Categories: News

LENSAR to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Mr. Curtis’ presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021 and can be accessed through the Investors section of the Company’s website at https://ir.lensar.com. The webcast will be available for one month after the presentation has been posted.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.

Contacts

Thomas R. Staab, II, CFO

ir.contact@lensar.com

Lee Roth / Cameron Radinovic

Burns McClellan for LENSAR

lroth@burnsmc.com / cradinovic@burnsmc.com

Staff

Recent Posts

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an…

34 minutes ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:…

34 minutes ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the…

35 minutes ago

Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline

VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical…

35 minutes ago

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH

LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and…

35 minutes ago

Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Participants treated with gildeuretinol in the SAGA study in geographic atrophy (GA) secondary to age-related…

35 minutes ago